Financial PerformanceFILSPARI 2Q25 revenue came in at $71.9 million, ahead of the $61.6 million estimate, highlighting continued adoption in IgAN.
Licensing And CollaborationTravere has licensed FILSPARI to Renalys Pharma for development and commercialization in Japan, South Korea, Taiwan, and 10 Southeast Asian countries, with potential milestone and royalty benefits.
Regulatory ApprovalFDA approved an update to the REMS labeling for FILSPARI, reducing the frequency of liver function monitoring and removing the pregnancy monitoring requirement.
Revenue GrowthRoyalty revenue growth from recently launched or acquired products are expected to boost financial results for LGND in 2H25, along with new sources of revenue brought on board early in the third quarter.